Evaluation of the antiemetic effect of domperidon in patients treated with cytostatic drugs.
Forty patients with various neoplastic syndromes received domperidon as a drug reducing nausea and vomiting. The drug prevents in the daily dose of 30 mg completely the occurrence of nausea and vomiting in 30% of the patients and in 58% considerably reduces their intensity. The dose of 60 mg abolishes nausea and vomiting in 60% of the patients and alleviates in 35%. The drug had been administered through the whole period of chemotherapy without any side effects which may be attributed to its antagonist action to dopamine.
Polubiec
A
A
Department of Internal Diseases and Haematology, University Medical School in Warsaw.
Krasnopolska-Polanczky
Z
Z
Duda-Król
W
W
Jórasz
I
I
Witkowski
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D004294:Domperidone / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology; D012720:Severity of Illness Index; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology
D004294:Domperidone